Optimal antiplatelet therapy during percutaneous coronary interventions includes glycoprotein IIb/IIIa inhibitors just eliminate the infusion

J Am Coll Cardiol. 2009 Mar 10;53(10):846-8. doi: 10.1016/j.jacc.2008.12.004.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Angioplasty, Balloon, Coronary*
  • Combined Modality Therapy
  • Coronary Disease / therapy
  • Drug Administration Schedule
  • Eptifibatide
  • Hemorrhage / chemically induced
  • Hemorrhage / epidemiology
  • Humans
  • Infusions, Intravenous
  • Peptides / administration & dosage*
  • Peptides / adverse effects
  • Platelet Aggregation Inhibitors / administration & dosage*
  • Platelet Aggregation Inhibitors / adverse effects
  • Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors*
  • Stents

Substances

  • Peptides
  • Platelet Aggregation Inhibitors
  • Platelet Glycoprotein GPIIb-IIIa Complex
  • Eptifibatide